Phase 3 GAN Clinical Trials
21 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 21 trials
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled235 locationsNCT06935357
Recruiting
Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled404 locationsNCT05675410
Recruiting
Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 3
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Pyoderma Gangrenosum
Boehringer Ingelheim90 enrolled97 locationsNCT06624670
Recruiting
Phase 2Phase 3
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
Gangliosidoses, GM2Gangliosidosis, GM1
Azafaros A.G.75 enrolled36 locationsNCT07082543
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
GM1 GangliosidosisGM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.147 enrolled37 locationsNCT07054515
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 2Phase 3
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Nationwide Children's Hospital500 enrolled32 locationsNCT05267821
Recruiting
Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 3
Anesthesia sTrategy foR Organ Procurement In braiN dEath
Brain-dead Organ Donors
University Hospital, Grenoble270 enrolled1 locationNCT07166991
Recruiting
Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 3
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled1 locationNCT07390123
Recruiting
Phase 3
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB)Ganglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology5 enrolled1 locationNCT07375563
Recruiting
Phase 3
Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure
Organ Grafts
Nantes University Hospital332 enrolled3 locationsNCT06235892
Recruiting
Phase 3
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.360 enrolled1 locationNCT06819826
Recruiting
Phase 3
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology15 enrolled1 locationNCT06071897
Completed
Phase 3
Human Papilloma Virus (HPV) Vaccination in Special Risk Groups
Special Risk Groups
1. Paediatric Rheumatalogical Disease
2. Inflammatory Bowel Disease
3. Acute Lymphoblastic Leukaemia
4. Solid Organ Transplant Recipients (kidney and liver)
5. Chronic Renal Disease
6. Bone Marrow Transsplant
The response to the HPV vaccine will be studied within these 6 special risk groups.
National Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation100 enrolled1 locationACTRN12609000571279